放射線部ー治療部門
2020年度 論文・学会発表

学術雑誌

欧　文

〈他施設との共同研究〉

1. Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Narabayashi M, Ishida Y, Sakamoto M, Fujishiro S, Katagiri T, Kim YH, Mizowaki T：Incidence and risk factors of symptomatic radiation pneumonitis in non−small−cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clinical Lung Cancer 2021；DOI：10.1016/j.cllc.2021.01.017.
2. Fujii K, Sakanaka K, Uozumi R, Ishida Y, Inoo H, Tsunoda S, Miyamoto S, Muto M, Mizowaki T : Association of chemoradiotherapy with thoracic vertebral fractures in Patients with esophageal cancer. JAMA Network Open 2020；3(9)：e 2013952.
3. Nakamura K, Ishikawa H, Akimoto T, Aoki M, Kariya S, Kawamura H, Kumano T, Kozuka T, Konishi K, Sakaguchi M, Takayama K : National survey of radiation oncologists’ practice patterns regarding hormone−naïve prostate cancer with bone metastases. Journal of Clinical Oncology 2020；50(10)：1188−1194.
4. Sato GE, Aizawa R, Nakamura K, Takayama K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T : Long−term clinical outcomes of salvage pelvic radiation therapy for oligo−recurrent pelvic lymph nodes after definitive external−beam radiation therapy for non−metastatic prostate cancer. Journal of Radiation Research 2020；61(4)：622−628.
5. Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T：Increased risk of disease progression in younger men：Analysis of factors predicting biochemical failure and castration−resistant prostate cancer after high−dose intensity−modulated radiation therapy for nonmetastatic prostate cancer. Urologic Oncology. 2021；39(2)：131.e9−131.e 15.

邦　文

〈他施設との共同研究〉

6. 飯間 麻美，飯塚 裕介，松尾 幸憲，高山 賢二，中本 裕士，山本 憲，片岡 正子，石守 崇好，溝脇 尚志，富樫 かおり：腫瘍の「顔」をとらえる―生物学的不均一性に応じた放射線治療の幕開け― 機能と解剖を繋ぐMRI放射線治療への新たな展開．医学物理2020；40(1)：3-7．